Long-term results of Ahmed glaucoma valve implantation with/without intravitreal anti-VEGF injection in neovascular glaucoma patients Résultats à long terme de l'implantation de la valve de Ahmed avec ou sans injection intravitréenne d'anti-VEGF chez les patients atteints de glaucome néovasculaire

ŞAHİN V., AYAZ Y., Yücel İ., Şen E.

Journal Francais d'Ophtalmologie, cilt.47, sa.8, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Sayı: 8
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1016/j.jfo.2024.104240
  • Dergi Adı: Journal Francais d'Ophtalmologie
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, Veterinary Science Database
  • Anahtar Kelimeler: Glaucoma drainage implants, Intraocular pressure, Intravitreal injections, Neovascular glaucoma, Visual acuity
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Purpose: This study aimed to evaluate the efficacy of Ahmed glaucoma valve (AGV) implantation with or without anti-VEGF injections in neovascular glaucoma patients. Materials and methods: This single-center retrospective study assessed NVG patients who underwent AGV implantation with or without anti-VEGF injections. Demographic and clinical data, including ocular findings, intraocular pressure (IOP), visual acuity, and glaucoma medication count, were recorded preoperatively and postoperatively at one day, one month, and one year. The study included 35 patients. Group 1 consisted of 23 patients who received anti-VEGF injections before AGV surgery. Group 2, with 12 patients, had no anti-VEGF injections prior to surgery. Successful surgery was defined as IOP values between 6 and 21 mmHg. The primary outcome was a 30% or more reduction in IOP. Results: The groups displayed no significant difference in their demographic or clinical profiles (P > 0.05). The visual acuity before and one year after surgery did not differ significantly between the groups. However, IOP values significantly decreased by the end of the one-year follow-up for both groups. No significant differences were found between the groups regarding visual acuity, IOP, or the number of medications during the one-year follow-up (P > 0.05). Success rates were 95.7% for Group 1 and 91.7% for Group 2. No significant difference in complications between the groups was observed (P > 0.05). Conclusion: Anti-VEGF injections prior to AGV implantation did not significantly impact visual acuity, IOP values, or medication count during the one-year follow-up.